PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.29%
EBIT growth below 50% of TRVN's 14.24%. Michael Burry would suspect deeper competitive or cost structure issues.
3.29%
Operating income growth under 50% of TRVN's 14.24%. Michael Burry would be concerned about deeper cost or sales issues.
27.01%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
26.90%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
26.90%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.31%
OCF growth under 50% of TRVN's 37.31%. Michael Burry might suspect questionable revenue recognition or rising costs.
3.31%
FCF growth under 50% of TRVN's 37.31%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.36%
Negative 10Y OCF/share CAGR while TRVN stands at 49.15%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-12.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-12.36%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
44.63%
Net income/share CAGR at 50-75% of TRVN's 60.68%. Martin Whitman might question if the firm’s product or cost base lags behind.
44.63%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
44.63%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
-80.42%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-80.42%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-80.42%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-16.23%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
14.30%
We have some new debt while TRVN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-4.62%
We cut SG&A while TRVN invests at 10.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.